Record: 41

12/24/2020

Daily Note

Pages: 3

CSO Resigns, Added to the Board; Potential Sulopenem NDA Acceptance Next Month; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Record: 42

12/01/2020

Company Report

Pages: 2

Sulopenem Submitted to FDA -- Sell

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 43

12/01/2020

Daily Note

Pages: 3

Sulopenem NDA Submitted for Quinolone-Resistant uUTI; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Record: 44

11/17/2020

Company Report

Pages: 7

3Q20 Recap; Sulopenem uUTI NDA Filing Imminent for 2H21 PDUFA

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Record: 45

10/26/2020

Company Report

Pages: 2

Downward Spiral Continues with Offering

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 46

10/01/2020

Company Report

Pages: 2

NDA Filing in Q4

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 47

09/30/2020

Daily Note

Pages: 3

Regulatory Pathway Confirmed for Sulopenem in Subset of uUTI, but Near-Term Overhangs Remain

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Record: 48

09/03/2020

Company Report

Pages: 2

Wrong Number on Rights - Sell

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 49

09/02/2020

Company Report

Pages: 2

Rights Buy a Little Time

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 50

08/10/2020

Company Report

Pages: 7

Awaiting FDA Meeting at End of 3Q20 to Elucidate Sulopenem''s U.S. Regulatory Path; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Record: 51

07/15/2020

Company Report

Pages: 2

Wrong Time for Rights - Sell

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 52

06/30/2020

Company Report

Pages: 2

UUTI Halfway There, NDA Livin? on a Prayer

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 53

06/16/2020

Company Report

Pages: 6

Sulopenem Failed Phase 3 cUTI Trial; Downgrade to Neutral and Remove PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Record: 54

06/04/2020

Company Report

Pages: 2

Bridge to Last Data Readout

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 55

06/02/2020

Company Report

Pages: 2

Beginning of the End?

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 56

05/15/2020

Company Report

Pages: 2

Q1 Results

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 57

05/15/2020

Company Report

Pages: 8

1Q20 Recap: Imminent Make or Break Readouts in UTI; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Record: 58

03/13/2020

Company Report

Pages: 8

4Q Recap: Data Catalysts Imminent With Two Phase 3 Readouts; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Record: 59

01/31/2020

Company Report

Pages: 6

Awaiting Pivotal UTI Data for Sulopenem in 1Q20; Affirm Buy, Reduce PT to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Record: 60

01/21/2020

Company Report

Pages: 2

No Longer Worth the Risk - Sell

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00